Patents by Inventor Chang-Hee Min

Chang-Hee Min has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140235559
    Abstract: Disclosed is an anticancer pharmaceutical composition comprising phenformin or a pharmaceutically acceptable salt thereof, and 2-deoxy-D-glucose as active ingredients. These ingredients act in synergy with each other, thus exhibiting more potent inhibitory activity against the growth of cancer cells, compared to individual ingredients. Also, the synergistic anticancer activity allows the individual drugs to be used in lower amounts, which leads to a reduction in the occurrence of adverse effects. In addition, the time-lag release or administration of the ingredients decreases blood lactic acid levels to significantly mitigate the adverse effect of lactic acidosis, as well as exerting high anticancer effects. Particularly, the pharmaceutical composition can be formulated to dosage forms effective for therapy, increasing the drug compliance of the subject.
    Type: Application
    Filed: June 15, 2011
    Publication date: August 21, 2014
    Applicant: Hanall Biopharma Co., Ltd.
    Inventors: Sung-Wuk Kim, Sung-Soo Jun, Chang-Hee Min, Ja-Seong Koo, Jin-Wook Kim, Yong-Eun Kim, Sang-Ouk Sun
  • Publication number: 20140235558
    Abstract: Disclosed is an anticancer pharmaceutical composition comprising phenformin or a pharmaceutically acceptable salt thereof, and a glycolysis inhibitor, particularly, 2-deoxy-D-glucose as active ingredients. These ingredients act in synergy with each other, thus exhibiting more potent inhibitory activity against the growth of cancer cells, compared to individual ingredients. Also, the synergistic anticancer activity allows the individual drugs to be used in lower amounts, which leads to a reduction in the occurrence of adverse effects. In addition, the time-lag release or administration of the ingredients decreases blood lactic acid levels to significantly mitigate the adverse effect of lactic acidosis, as well as exerting high anticancer effects. Particularly, the pharmaceutical composition can be formulated to dosage forms effective for therapy, increasing the drug compliance of the subject.
    Type: Application
    Filed: June 28, 2013
    Publication date: August 21, 2014
    Inventors: Sung-Wuk Kim, Sung-Soo Jun, Chang-Hee Min, Ja-Seong Koo, Jin-Wook Kim, Yong-Eun Kim, Sang-Ouk Sun
  • Patent number: 6747050
    Abstract: The present invention provides to an isoxazoline derivative of formula (I), the pharmaceutically acceptable salts, esters and stereochemically isomeric forms thereof, and the use of the derivative in inhibiting the activity of caspases. The present invention also provides a pharmaceutical composition for preventing inflammation and apoptosis which comprise the isoxazoline derivative, pharmaceutically acceptable salts, esters and stereochemically isomeric forms thereof and the process for preparing the same. The derivative according to the present invention can be effectively used in treating diseases due to caspases, such as, for example the disease in which cells are abnormally died, dementia, cerebral stroke, AIDS, diabetes, gastric ulcer, hepatic injury by hepatitis, sepsis, organ transplantation rejection reaction and anti-inflammation.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: June 8, 2004
    Assignee: LG Chem Investment Ltd.
    Inventors: Eunice Eun-Kyeong Kim, Mi-Jeong Park, Tae-Hee Lee, Hye-Kyung Chang, Tae-Kyo Park, Chang-Yuil Kang, Young-Myeong Kim, Kwang-Yul Moon, Young-Leem Oh, Chang-Hee Min, Hyun-Ho Chung